KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Financing Activities: 2013-2025

Historic Cash from Financing Activities for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to -$65.3 million.

  • Travere Therapeutics' Cash from Financing Activities fell 142141.30% to -$65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.0 million, marking a year-over-year increase of 11412.10%. This contributed to the annual value of $139.4 million for FY2024, which is 36.66% down from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Cash from Financing Activities is -$65.3 million, which was down 4,529.76% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Cash from Financing Activities registered a high of $217.6 million during Q1 2023, and its lowest value of -$65.3 million during Q3 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $782,000 (2024), whereas its average is $27.2 million.
  • As far as peak fluctuations go, Travere Therapeutics' Cash from Financing Activities spiked by 36,223.50% in 2024, and later slumped by 142,141.30% in 2025.
  • Over the past 5 years, Travere Therapeutics' Cash from Financing Activities (Quarterly) stood at $39.3 million in 2021, then tumbled by 97.06% to $1.2 million in 2022, then slumped by 66.84% to $383,000 in 2023, then skyrocketed by 36,223.50% to $139.1 million in 2024, then tumbled by 142,141.30% to -$65.3 million in 2025.
  • Its Cash from Financing Activities was -$65.3 million in Q3 2025, compared to $1.5 million in Q2 2025 and $3.7 million in Q1 2025.